Samer Al Hadidi

Samer Al Hadidi: Daratumumab for high-risk smoldering multiple myeloma – Are we there yet?

Samer Al Hadidi, Associate Professor at UAMS – University of Arkansas for Medical Sciences, posted on X:

“Check our recent editorial discussing AQUILA study.

Daratumumab for high-risk smoldering multiple myeloma – are we there yet?”

Authors: Bhavesh Mohan Lal, Samer Al Hadidi

Samer Al Hadidi

Read more posts featuring Myeloma at OncoDaily.com.